Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
Perspective Therapeutics, Inc. (CATX)
Company Research
Source: GlobeNewswire
SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates on the Company’s radiopharmaceutical programs being presented at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM") held in Hamburg, Germany, from October 19-23, 2024. “The preclinical studies and first-in-human imaging data presented with [212Pb]Pb-PSV359, our novel cyclic peptide targeting fibroblast activation protein-alpha, are very encouraging and validate the potential of this radiopharmaceutical in treating a variety of epithelial-derived cancers,” said Thijs Spoor, Perspective’s CEO. “We also note the valuable contributions from our scientists, collaborators and independent investigators to advancing the development of our potential new medicines, including updated safety and
Show less
Read more
Impact Snapshot
Event Time:
CATX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CATX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CATX alerts
High impacting Perspective Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CATX
News
- Perspective Therapeutics, Inc. (NYSE: CATX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock, down previously from $20.00.MarketBeat
- Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical SymposiumGlobeNewswire
- Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024GlobeNewswire
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 ResultsGlobeNewswire
- Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial ResultsGlobeNewswire
CATX
Earnings
- 11/12/24 - In-Line
CATX
Sec Filings
- 11/21/24 - Form 8-K
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- CATX's page on the SEC website